Drug Trial Radar · NCT06846710
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
May 2, 2025
Primary completion
Jul 14, 2026
Study completion Jul 14, 2026
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis .
Conditions
- Psoriasis
Interventions
HS-20118Drug
Single and multiple ascending doses of HS-20118 orally
HS-20118 placeboOther
Single and multiple ascending doses of HS-20118-matched placebo orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuationTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
- Number of participants with abnormalities of physical examinationTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
- Number of participants with abnormalities of vital signsTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
- Number of participants with clinical laboratory abnormalitiesTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
- Number of participants with abnormalities of electrocardiogram (ECG) parametersTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Kinetic Clinical Research
Anaheim, California
Clinitiative - Floridian Clinical Research, LLC
Miami Lakes, Florida
NuLine Clinical Trial Center (Network)
Pompano Beach, Florida
Pacific Clinical Research Network (PCRN), Auckland
Takapuna, Auckland, New Zealand
Pacific Clinical Research Network (PCRN), Christchurch
Christchurch, Christchurch, New Zealand
Momentum Clinical Research, Dunedin
Dunedin, Dunedin, New Zealand
Momentum Clinical Research, Pukekohe
Pukekohe, Pukekohe, New Zealand
Pacific Clinical Research Network (PCRN), Wellington
Upper Hutt, Upper Hutt, New Zealand
Momentum Clinical Research, Wellington
Mount Cook, Wellington Region, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.